News

AOD-9604 vs. Semaglutide Bone Risk: What the New GLP-1 Bone Study Means
New rodent data links semaglutide to reduced bone formation, raising questions about fracture risk. Could fragment peptides like AOD-9604 offer fat loss Read more...
ACP First-Line Recommendation: What Semaglutide's New Clinical Guidelines Mean for Your Weight Loss Protocol
The ACP now lists semaglutide as first-line pharmacotherapy for obesity. What does this mean for weight-loss protocols, and where do other metabolic peptides fit? Read more...